BB Biotech AG (BION.SW)
CHF 36.75
(0.68%)
CHF 36.75
(0.68%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | -199.56 Million CHF | 43.18% |
| 2022 | -351.22 Million CHF | 11.36% |
| 2021 | -396.22 Million CHF | -156.66% |
| 2020 | 699.23 Million CHF | 2.04% |
| 2019 | 685.23 Million CHF | 247.12% |
| 2018 | -465.75 Million CHF | -167.2% |
| 2017 | 693.05 Million CHF | 187.02% |
| 2016 | -796.44 Million CHF | -220.82% |
| 2015 | 659.22 Million CHF | -55.35% |
| 2014 | 1.47 Billion CHF | 57.42% |
| 2013 | 937.89 Million CHF | 148.9% |
| 2012 | 376.82 Million CHF | 29794.25% |
| 2011 | -1.26 Million CHF | -180.42% |
| 2010 | 1.57 Million CHF | -97.09% |
| 2009 | 54.29 Million CHF | -26.45% |
| 2008 | 73.82 Million CHF | 0.0% |
| 2007 | - CHF | -100.0% |
| 2006 | 318.06 Million CHF | -4.39% |
| 2005 | 332.66 Million CHF | 55.7% |
| 2004 | 213.65 Million CHF | 10.41% |
| 2003 | 193.51 Million CHF | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | -149.68 Million CHF | -88.68% |
| 2024 Q1 | 262.26 Million CHF | 135.92% |
| 2024 Q2 | -79.33 Million CHF | -130.25% |
| 2023 FY | -199.56 Million CHF | 43.18% |
| 2023 Q4 | 111.17 Million CHF | 373.12% |
| 2023 Q3 | -40.7 Million CHF | -770.67% |
| 2023 Q2 | -4.67 Million CHF | 98.15% |
| 2023 Q1 | -252.09 Million CHF | -650.32% |
| 2022 FY | -351.22 Million CHF | 11.36% |
| 2022 Q4 | -33.59 Million CHF | -115.23% |
| 2022 Q2 | -222.52 Million CHF | 25.33% |
| 2022 Q3 | 220.63 Million CHF | 199.15% |
| 2022 Q1 | -298.02 Million CHF | -59.23% |
| 2021 FY | -396.22 Million CHF | -156.66% |
| 2021 Q1 | 223.06 Million CHF | -67.19% |
| 2021 Q2 | 143.22 Million CHF | -35.79% |
| 2021 Q3 | -192.64 Million CHF | -234.5% |
| 2021 Q4 | -187.17 Million CHF | 2.84% |
| 2020 Q3 | -382.8 Million CHF | -132.13% |
| 2020 FY | 699.23 Million CHF | 2.04% |
| 2020 Q4 | 679.8 Million CHF | 277.59% |
| 2020 Q2 | 1.19 Billion CHF | 259.58% |
| 2020 Q1 | -746.48 Million CHF | -243.92% |
| 2019 Q4 | 518.66 Million CHF | 252906.83% |
| 2019 Q2 | -369.94 Million CHF | -163.91% |
| 2019 Q1 | 578.86 Million CHF | 384.25% |
| 2019 FY | 685.23 Million CHF | 247.12% |
| 2019 Q3 | 205 Thousand CHF | 100.06% |
| 2018 Q4 | -203.64 Million CHF | -180.22% |
| 2018 Q2 | 1.06 Million CHF | -58.76% |
| 2018 FY | -465.75 Million CHF | -167.2% |
| 2018 Q1 | 2.58 Million CHF | 101.8% |
| 2018 Q3 | 253.87 Million CHF | 23715.29% |
| 2017 Q4 | -143.65 Million CHF | -138.39% |
| 2017 Q3 | 374.2 Million CHF | 230.91% |
| 2017 Q2 | 113.08 Million CHF | -69.99% |
| 2017 FY | 693.05 Million CHF | 187.02% |
| 2017 Q1 | 376.78 Million CHF | 1764.69% |
| 2016 Q4 | -22.63 Million CHF | -105.65% |
| 2016 Q1 | -1.2 Billion CHF | -334.65% |
| 2016 Q3 | 400.56 Million CHF | 799.54% |
| 2016 FY | -796.44 Million CHF | -220.82% |
| 2016 Q2 | 44.53 Million CHF | 103.7% |
| 2015 Q3 | -564.41 Million CHF | -262.13% |
| 2015 FY | 659.22 Million CHF | -55.35% |
| 2015 Q4 | 512.89 Million CHF | 190.87% |
| 2015 Q2 | 348.11 Million CHF | -8.79% |
| 2015 Q1 | 381.66 Million CHF | -47.61% |
| 2014 Q4 | 728.55 Million CHF | 48.88% |
| 2014 Q3 | 489.36 Million CHF | 142.72% |
| 2014 Q2 | 201.61 Million CHF | 200.06% |
| 2014 FY | 1.47 Billion CHF | 57.42% |
| 2014 Q1 | 67.19 Million CHF | -34.45% |
| 2013 Q2 | 139.74 Million CHF | -61.18% |
| 2013 Q3 | 343.85 Million CHF | 146.06% |
| 2013 Q4 | 102.5 Million CHF | -70.19% |
| 2013 FY | 937.89 Million CHF | 148.9% |
| 2013 Q1 | 360 Million CHF | 356.64% |
| 2012 Q2 | - CHF | -100.0% |
| 2012 Q3 | 153.68 Million CHF | 0.0% |
| 2012 Q4 | -140.27 Million CHF | -191.27% |
| 2012 Q1 | 199.1 Million CHF | 13869.23% |
| 2012 FY | 376.82 Million CHF | 29794.25% |
| 2011 Q3 | -852 Thousand CHF | 0.0% |
| 2011 Q1 | - CHF | -100.0% |
| 2011 FY | -1.26 Million CHF | -180.42% |
| 2011 Q4 | -1.44 Million CHF | -69.72% |
| 2011 Q2 | - CHF | 0.0% |
| 2010 Q3 | 38.71 Million CHF | 96685.0% |
| 2010 Q4 | 9000.00 CHF | -99.98% |
| 2010 Q1 | 45.05 Million CHF | 165.03% |
| 2010 FY | 1.57 Million CHF | -97.09% |
| 2010 Q2 | 40 Thousand CHF | -99.91% |
| 2009 Q2 | 97.4 Million CHF | 211.3% |
| 2009 Q3 | 114.21 Million CHF | 17.25% |
| 2009 Q4 | -69.28 Million CHF | -160.66% |
| 2009 FY | 54.29 Million CHF | -26.45% |
| 2009 Q1 | -87.52 Million CHF | 0.0% |
| 2008 FY | 73.82 Million CHF | 0.0% |
| 2007 FY | - CHF | -100.0% |
| 2006 FY | 318.06 Million CHF | -4.39% |
| 2005 FY | 332.66 Million CHF | 55.7% |
| 2004 FY | 213.65 Million CHF | 10.41% |
| 2003 FY | 193.51 Million CHF | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Addex Therapeutics Ltd | 1.61 Million CHF | 12440.371% |
| Basilea Pharmaceutica AG | 157.63 Million CHF | 226.601% |
| Evolva Holding SA | 9.43 Million CHF | 2214.55% |
| Idorsia Ltd | 152.38 Million CHF | 230.962% |
| Kuros Biosciences AG | 33.56 Million CHF | 694.586% |
| Molecular Partners AG | 7.03 Million CHF | 2935.564% |
| Relief Therapeutics Holding AG | 6.03 Million CHF | 3407.923% |
| Santhera Pharmaceuticals Holding AG | 103.41 Million CHF | 292.979% |